Tumor Response in Hypofractionated Radiotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-30

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will follow-up different immune cell populations in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of Local Hypofractionated Radiotherapy and a rationale for adjuvant immunotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers for Prediction of Tumor Response to Radiotherapy

NCT03744819

Solid Tumors

RECRUITING

Investigating the Tumour Immune Response of Radiotherapy

NCT05076500

Cancer

RECRUITING

Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response

NCT02439008

Carcinoma, Hepatocellular Colorectal Neoplasms Melanoma +1 more

TERMINATED NA

Low-dose Radiotherapy Combined With Conventional Fractionated Radiotherapy in Lung Cancer After Immunotherapy Resistance

NCT05906329

Cancer Patients

UNKNOWN NA

Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer

NCT05994300

Cervical Neoplasm Adaptive Radiotherapy Radiotherapy; Adverse Effect

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Patient information and collection of a signed informed consent form
* Clinical data collection
* Blood samples of 5 mL:

1. after registration, prior to the first fraction of radiotherapy
2. during radiotherapy sessions
3. one month, 3 months after the last radiotherapy session
* Storage of the blood samples at ambient temperature
* Transportation of the samples to the Institute of Biology of Lille (IBL) - CNRS UMR8161 for analysis
* Destruction of the samples at the end of the analysis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient requiring a hypofractionated irradiation;
* pathologically confirmed Unspecified Adult Solid Tumor
* Age ≥ 18 years old
* KPS≥70
* Signed written informed consent.

Exclusion Criteria

* Patient treated by chemotherapy, targeted or immunotherapy within 21 days before the first sampling,
* Pregnant or breastfeeding woman,
* Patient under guardianship or tutorship.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No